European Commission approves AstraZeneca's Tagrisso combined with chemotherapy for first-line treatment of advanced EGFR mutated non-small cell lung cancer.
The European Commission has approved AstraZeneca's Tagrisso (osimertinib) combined with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced EGFR mutated (EGFRm) non-small cell lung cancer (NSCLC) with exon 19 deletions or exon 21 (L858R) mutations. The approval follows a recommendation from the European Medicines Agency's human medicines committee and is based on the results of the FLAURA2 Phase III trial, which showed the combination therapy reduced the risk of disease progression or death by 38% compared to Tagrisso monotherapy.
July 08, 2024
3 Articles